Friday, March 12, 2010
Erik Aarden (Maastricht University) studied whether healthcare systems include new technologies in the basic insurance package and whether patients are given access to these.
This research focused on three genetic technologies: pre-implantation genetic diagnostics whereby in-vitro fertilisation is combined with genetic research; monitoring for hereditary breast cancer; diagnosis and treatment of familial hypercholesterolaemia, an affliction that seriously increases the risk of cardiovascular diseases.
Erik Aarden signals significant differences in the approach taken
in the Netherlands, England and Germany. His study was conducted within the 'The Societal Component of Genomics Research' programme (MCG Programme – concluded in 2008).
Read more